Exagen Q2 2024 GAAP EPS $(0.16) Beats $(0.34) Estimate, Sales $15.064M Beat $13.133M Estimate
Portfolio Pulse from Benzinga Newsdesk
Exagen (NASDAQ:XGN) reported Q2 2024 GAAP EPS of $(0.16), beating the $(0.34) estimate, and sales of $15.064M, surpassing the $13.133M estimate. This represents a significant improvement in both earnings and sales compared to the same period last year.
August 05, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exagen (NASDAQ:XGN) reported better-than-expected Q2 2024 results with GAAP EPS of $(0.16) beating the $(0.34) estimate and sales of $15.064M surpassing the $13.133M estimate. This indicates a significant improvement in both earnings and sales compared to the same period last year.
Exagen's better-than-expected earnings and sales figures for Q2 2024 are likely to positively impact its stock price in the short term. The significant improvement in both metrics compared to the same period last year suggests strong operational performance and could boost investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100